Myxoinflammatory fibroblastic sarcoma (MIFS) has been shown to harbor various recurrent molecular aberrations; most of which, however, seem to be present in only a minority of cases. In order to better characterize the molecular underpinnings of MIFS, fourteen cases were analyzed by targeted RNA-sequencing (RNA-seq), VGLL3 enumeration FISH probe, and BRAF break-apart and enumeration probes. Neither t(1;10)(p22;q24) nor BRAF gene amplifications were found. However, VGLL3 gene amplification was detected in 5 cases by FISH which corresponded with an increase in VGLL3 expression detected by RNA-seq. In 1 of these cases, RNA-seq additionally revealed a novel SND1::BRAF fusion. Two of the 9 cases lacking VGLL3 amplification harbored either a SEC23IP::VGLL3 or a TEAD1::MRTFB rearrangement by RNA-seq, both confirmed by RT-PCR and Sanger sequencing. The detected molecular aberrations have a potential to either activate the expression of genes regulated by the transcription factors of the TEAD family, which are involved in tumor initiation and progression, or switch on the MEK/ERK signaling cascade, which plays an important role in cell cycle progression. Our results broaden the molecular genetic spectrum of MIFS and point toward the importance of the VGLL3-TEAD interaction, as well as the deregulation of the MEK/ERK pathway in the pathogenesis of MIFS, and may represent a potential target for therapy of recurrent or advanced disease.

Bioptical Laboratory Ltd Pilsen Czech Republic

Department of Pathology Faculty of Medicine in Pilsen Charles University Alej Svobody 80 323 00 Pilsen Czech Republic

Institute of Pathology Friedrich Alexander University Erlangen Nürnberg University Hospital Erlangen Erlangen Germany

See more in PubMed

Montgomery EA, Devaney KO, Giordano TJ, Weiss SW (1998) Inflammatory myxohyaline tumor of distal exterimities with virocyte or Reed Sternberg-like cells: a distinctive lesion with features simulating inflammatory conditions, Hodgkin’s disease and various sarcomas. Mod Pathol 11:384–391 PubMed

Meis-Kindblom JM, Kindblom LG (1998) Acral myxoinflammatory fibroblastic sarcoma: a low-grade tumor of the hands and feet. Am J Surg Pathol 22:911–924 DOI

Michal M (1998) Inflammatory myxoid tumor of the soft parts with bizarre giant cells. Pathol Res Pract 194(8):533–529 DOI

Suster D, Michal M, Huang H et al (2020) Myxoinflammatory fibroblastic sarcoma: an immunohistochemical and molecular genetic study of 73 cases. Mod Pathol 33(12):2520–2533 DOI

Michal M, Kazakov DV, Hadravský L, Kinkor Z, Kuroda N, Michal M (2015) High-grade myxoinflammatory fibroblastic sarcoma: a report of 23 cases. Ann Diagn Pathol 19(3):157–163 DOI

WHO classification of tumours editorial board (2020) WHO classification of tumours of soft tissue and bone, 5th edn. IARC Press, Lyon, France

Michal M, Rubin BP, Kazakov DV et al (2020) Inflammatory leiomyosarcoma shows frequent co-expression of smooth and skeletal muscle markers supporting a primitive myogenic phenotype: a report of 9 cases with a proposal for reclassification as low-grade inflammatory myogenic tumor. Virchows Arch 477(2):219–230 DOI

Agaimy A, Tögel L, Haller F, Zenk J, Hornung J, Märkl B (2020) YAP1-NUTM1 gene fusion in porocarcinoma of the external auditory canal. Head Neck Pathol 14(4):982–990 DOI

Kao YC, Ranucci V, Zhang L et al (2017) Recurrent BRAF gene rearrangements in myxoinflammatory fibroblastic sarcomas, but not hemosiderotic fibrolipomatous tumors. Am J Surg Pathol 41(11):1456–1465 DOI

Arbajian E, Hofvander J, Magnusson L, Mertens F (2020) Deep sequencing of myxoinflammatory fibroblastic sarcoma. Genes Chromosomes Cancer 59:309–317 DOI

Hallor KH, Sciot R, Staaf J et al (2009) Two genetic pathways, t(1;10) and amplification of 3p11-12, in myxoinflammatory fibroblastic sarcoma, hemosiderotic fibrolipomatous tumor, and morphologically similar lesions. J Pathol 217:716–727 DOI

Carter JM, Sukov WR, Montgomery E et al (2014) TGFBR3 and MGEA5 rearrangements in pleomorphic angiectatic tumor and the spectrum of related neoplasms. Am J Surg Pathol 38:1182–1992 DOI

Antonescu CR, Zhang L, Nielsen GP et al (2011) Consistent t(1;10) with rearrangements of TGFBR3 and MGEA5 in both myxoinflammatory fibroblastic sarcoma and hemosiderotic fibrolipomatous tumor. Genes Chromosomes Cancer 50:757–764 DOI

Zreik RT, Carter JM, Sukov WR et al (2016) TGFBR3 and MGEA5 rearrangements are much more common in “hybrid” hemosiderotic fibrolipomatous tumor-myxoinflammatory fibroblastic sarcomas than in classical myxoinflammatory fibroblastic sarcomas: a morphological and fluorescence in situ hybridization study. Hum Pathol 53:14–24 DOI

Hélias-Rodzewicz Z, Pérot G, Chibon F et al (2010) YAP1 and VGLL3, encoding two cofactors of TEAD transcription factors, are amplified and overexpressed in a subset of soft tissue sarcomas. Genes Chromosomes Cancer 49(12):1161–1171 DOI

Dickson BC, Antonescu CR, Demicco EG et al (2021) Hybrid schwannoma-perineurioma frequently harbors VGLL3 rearrangement. Mod Pathol 34(6):1116–1124 DOI

Figeac N, Mohamed AD, Sun C et al (2019) VGLL3 operates via TEAD1, TEAD3 and TEAD4 to influence myogenesis in skeletal muscle. J Cell Sci 132(13):jcs225946 DOI

Zanconato F, Cordenonsi M, Piccolo S (2016) YAP/TAZ at the roots of cancer. Cancer Cell 29(6):783–803 DOI

Hori N, Okada K, Takakura Y, Takano H, Yamaguchi N, Yamaguchi N (2020) Vestigial-like family member 3 (VGLL3), a cofactor for TEAD transcription factors, promotes cancer cell proliferation by activating the Hippo pathway. J Biol Chem 295(26):8798–8807 DOI

Dickson BC, Antonescu CR, Argyris PP et al (2018) Ectomesenchymal chondromyxoid tumor: a neoplasm characterized by recurrent RREB1-MKL2 fusions. Am J Surg Pathol 42(10):1297–1305 DOI

Makise N, Mori T, Kobayashi H et al (2020) Mesenchymal tumours with RREB1-MRTFB fusion involving the mediastinum: extra-glossal ectomesenchymal chondromyxoid tumours? Histopathology 76(7):1023–1031 DOI

Mechtersheimer G, Andrulis M, Delank KW et al (2021) RREB1-MKL2 fusion in a spindle cell sinonasal sarcoma: biphenotypic sinonasal sarcoma or ectomesenchymal chondromyxoid tumor in an unusual site? Genes Chromosomes Cancer 60(8):565–570 DOI

Flucke U, Tops BB, de Saint AubainSomerhausen N et al (2013) Presence of C11orf95-MKL2 fusion is a consistent finding in chondroid lipomas: a study of eight cases. Histopathology 62(6):925–930 DOI

Landin-Malt A, Benhaddou A, Zider A, Flagiello D (2016) An evolutionary, structural and functional overview of the mammalian TEAD1 and TEAD2 transcription factors. Gene 591(1):292–303 DOI

Shimoi W, Ezawa I, Nakamoto K et al (2005) p125 is localized in endoplasmic reticulum exit sites and involved in their organization. J Biol Chem 280(11):10141–10148 DOI

Mesrouze Y, Aguilar G, Bokhovchuk F et al (2020) A new perspective on the interaction between the Vg/VGLL1-3 proteins and the TEAD transcription factors. Sci Rep 10(1):17442 DOI

Zhang H, Ramakrishnan SK, Triner D et al (2015) Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1. Sci Signal 8(397):ra98 DOI

Zaman A, Wu W, Bivona TG (2019) Targeting oncogenic BRAF: past, present, and future. Cancers (Basel) 11(8):1197 DOI

Lee NV, Lira ME, Pavlicek A, et al (2012) A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation [published correction appears in PLoS One. 2012;7(8).]. PLoS One 7(6):e39653

Jang JS, Lee A, Li J et al (2015) Common oncogene mutations and novel SND1-BRAF transcript fusion in lung adenocarcinoma from never smokers. Sci Rep 5:9755 DOI

Jang JS, Wang X, Vedell PT et al (2016) Custom gene capture and next-generation sequencing to resolve discordant ALK status by FISH and IHC in lung adenocarcinoma. J Thorac Oncol 11(11):1891–1900 DOI

Chu YH, Wirth LJ, Farahani AA et al (2020) Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization. Mod Pathol 33(12):2458–2472 DOI

Sowalsky AG, Xia Z, Wang L et al (2015) Whole transcriptome sequencing reveals extensive unspliced mRNA in metastatic castration-resistant prostate cancer. Mol Cancer Res 13(1):98–106 DOI

Morgan GJ, He J, Tytarenko R et al (2018) Kinase domain activation through gene rearrangement in multiple myeloma. Leukemia 32(11):2435–2444 DOI